Form 4: Athira Pharma Director Grant Pickering Receives Stock Option Grant

Athira Pharma, Inc. Director Grant Pickering was granted 20,900 stock options with an exercise price of $0.3125, aligning his interests with the company's long-term performance.

Summary

• Grant Pickering, a Director at Athira Pharma, Inc. (ATHA), acquired 20,900 derivative securities in the form of stock options.
• The transaction date for this grant was May 30, 2025.
• Each stock option has an exercise price of $0.3125.
• The options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of Athira Pharma's stockholders that occurs after May 30, 2025.
• The expiration date for these options is May 29, 2035.
• The options were granted pursuant to the terms of Athira Pharma's Outside Director Compensation Policy.
• Following this transaction, Grant Pickering beneficially owns 20,900 stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of stock options to Director Grant Pickering aligns his financial interests directly with the long-term performance and shareholder value of Athira Pharma, Inc.
• This transaction is consistent with standard corporate governance practices for compensating outside directors, promoting retention and motivation.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a standard aspect of equity compensation plans.

Risks

• The value of the granted stock options is directly tied to the future market price of Athira Pharma's common stock, exposing the holder to market volatility and company-specific performance risks.
• There is no guarantee that the stock price will exceed the exercise price, meaning the options may not become 'in-the-money' or provide a financial benefit.

Future Outlook

The granted stock options are subject to a vesting schedule, with the earliest vesting occurring on May 30, 2026, or the day before the next annual meeting after May 30, 2025, indicating a future incentive for the director.

Management Comments

• The stock option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Industry Context

The grant of stock options to outside directors is a common practice within the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their interests with long-term company success.

Corporate Governance

Related Party Transactions

• The grant of stock options to Grant Pickering, a Director of Athira Pharma, Inc., constitutes a related party transaction as it involves compensation provided to an insider of the company.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned, but reflects the company's overall compensation philosophy for key personnel.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.

Key Dates

Keywords

Athira Pharma, ATHA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Grant Pickering, Biotechnology, Pharmaceuticals